PURPOSE: To report corneal toxicity of Mitomycin C application during filtering glaucoma surgery in two patients. CASE REPORTS: An elderly woman, 81 years of age, developed diffuse corneal epitheliopathy with subepithelial stromal oedema seven weeks after a trabeculectomy with Mitomycin C application. Another patient, a 76-year-old man, first developed a central epithelium defect and stromal oedema in the second postoperative week after a similar procedure. Later the corneal stroma melted, what resulted in perforation in the second postoperative month. RESULTS: Intraoperative Mitomycin C application during trabeculectomy induced serious corneal complications several weeks after the surgery. CONCLUSIONS: Although infrequent, serious corneal complications may arise following the intraoperative use of Mitomycin C in filtering surgery for glaucoma. The possible contributing factors to the development of the corneal toxicity will be discussed.
PURPOSE: To report corneal toxicity of Mitomycin C application during filtering glaucoma surgery in two patients. CASE REPORTS: An elderly woman, 81 years of age, developed diffuse corneal epitheliopathy with subepithelial stromal oedema seven weeks after a trabeculectomy with Mitomycin C application. Another patient, a 76-year-old man, first developed a central epithelium defect and stromal oedema in the second postoperative week after a similar procedure. Later the corneal stroma melted, what resulted in perforation in the second postoperative month. RESULTS: Intraoperative Mitomycin C application during trabeculectomy induced serious corneal complications several weeks after the surgery. CONCLUSIONS: Although infrequent, serious corneal complications may arise following the intraoperative use of Mitomycin C in filtering surgery for glaucoma. The possible contributing factors to the development of the corneal toxicity will be discussed.
Authors: Daniel J Gibson; Liya Pi; Sriniwas Sriram; Cong Mao; Bryon E Petersen; Edward W Scott; Andrew Leask; Gregory S Schultz Journal: Invest Ophthalmol Vis Sci Date: 2014-04-01 Impact factor: 4.799